Browse > Article

Sexually Dimorphic Control of Obesity and Skeletal Muscle Lipid Metabolism by Fenofibrate  

Lim, Hyesook (Department of Life Sciences, Mokwon University)
Lee, Hyunghee (Department of Life Sciences, Mokwon University)
Yoon, Michung (Department of Life Sciences, Mokwon University)
Abstract
Animals show a sexual dimorphism in metabolic responses. We investigated to verify whether the peroxisome proliferator-activated receptor ${\alpha}$ ($PPAR{\alpha}$) agonist fenofibrate regulates obesity and skeletal muscle lipid metabolism with sexual dimorphism and to determine the changes in skeletal muscle expression of $PPAR{\alpha}$ target genes. After both sexes of C57BL/6J mice received a high fat diet with or without fenofibrate for 7 weeks, we examined the effects of fenofibrate on not only body weight, adipose tissue mass, and skeletal muscle lipid accumulation, but also the mRNA expression of $PPAR{\alpha}$-related genes in skeletal muscle. Male mice given a fenofibrate-supplemented high fat diet showed decreased body weight gain and adipose tissue mass compared with mice fed a high fat diet alone, whereas fenofibrate did not reduce them in high fat diet-fed female mice. Lipid accumulation in skeletal muscle was inhibited by fenofibrate in male mice, but not in female mice. Gene expression analysis revealed that fenofibrate increased the mRNA levels of $PPAR{\alpha}$ target enzymes only in male mice. Therefore, our results suggest that sex-dependence differences in obesity and intramuscular lipid levels under fenofibrate treatment could be due in part to the differences in skeletal muscle $PPAR{\alpha}$ activation between male and female mice.
Keywords
Fenofibrate; $PPAR{\alpha}$; Sex; Skeletal muscle; Lipid metabolism;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Yoon M. PPAR${\alpha}$ in Obesity: Sex Difference and Estrogen Involvement. PPAR Res. 2010. 2010.
2 Laurent D, Gounarides JS, Gao J, Boettcher BR. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats. Diabetes Obes Metab. 2009. 11: 632-636.   DOI   ScienceOn
3 Mancini FP, Lanni A, Sabatino L, Moreno M, Giannino A, Contaldo F, Colantuoni V, Goglia F. Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats. FEBS Lett. 2001. 491: 154-158.   DOI   ScienceOn
4 Mandard S, Muller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci. 2004. 61: 393-416.   DOI   ScienceOn
5 Muoio DM, Way JM, Tanner CJ, Winegar DA, Kliewer SA, Houmard JA, Kraus WE, Dohm GL. Peroxisome proliferator-activated receptor-alpha regulates fatty acid utilization in primary human skeletal muscle cells. Diabetes. 2002. 51: 901-909.   DOI   ScienceOn
6 Mystkowski P, Schwartz MW. Gonadal steroids and energy homeostasis in the leptin era. Nutrition. 2000. 16: 937-946.   DOI   ScienceOn
7 Serrano A, Del Arco I, Javier Pavon F, Macias M, Perez-Valero V, Rodriguez de Fonseca F. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats. Neuropharmacology. 2008. 54: 226-234.   DOI   ScienceOn
8 Simoneau JA, Lortie G, Boulay MR, Thibault MC, Theriault G, Bouchard C. Skeletal muscle histochemical and biochemical characteristics in sedentary male and female subjects. Can J Physiol Pharmacol. 1985. 63: 30-35.   DOI   ScienceOn
9 Staels B. PPAR agonists and the metabolic syndrome. Therapie. 2007. 62: 319-326.   DOI   ScienceOn
10 Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998. 98: 2088-2093.   DOI   ScienceOn
11 Vega RB, Huss JM, Kelly DP. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol. 2000. 20: 1868-1876.   DOI   ScienceOn
12 Wade GN. Some effects of ovarian hormones on food intake and body weight in female rats. J Comp Physiol Psychol. 1975. 88: 183-193.   DOI   ScienceOn
13 Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes. 2001. 50: 411-417.   DOI   ScienceOn
14 Yoon M, Jeong S, Nicol CJ, Lee H, Han M, Kim JJ, Seo YJ, Ryu C, Oh GT. Fenofibrate regulates obesity and lipid metabolism with sexual dimorphism. Exp Mol Med. 2002. 34: 481-488.   DOI   ScienceOn
15 Yoon M, Jeong S, Lee H, Han M, Kang JH, Kim EY, Kim M, Oh GT. Fenofibrate improves lipid metabolism and obesity in ovariectomized LDL receptor-null mice. Biochem Biophys Res Commun. 2003. 302: 29-34.   DOI   ScienceOn
16 Yoon M. The role of PPAR${\alpha}$ in lipid metabolism and obesity: Focusing on the effects of estrogen on PPAR${\alpha}$ actions. Pharmacological Research. 2009. 60: 151-159.   DOI   ScienceOn
17 Costet P, Legendre C, More J, Edgar A, Galtier P, Pineau T. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem. 1998. 273: 29577-29585.   DOI
18 Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev. 1999. 20: 649-688.
19 Djouadi F, Aubey F, Schlemmer D, Bastin J. Peroxisome proliferator activated receptor delta (PPARdelta) agonist but not PPARalpha corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells. J Clin Endocrinol Metab. 2005. 90: 1791-1797.   DOI
20 Geary N, Asarian L. Estradiol increases glucagon's satiating potency in ovariectomized rats. Am J Physiol Regul Integr Comp Physiol. 2001. 281: R1290-R1294.   DOI
21 Green HJ, Fraser IG, Ranney DA. Male and female differences in enzyme activities of energy metabolism in vastus lateralis muscle. J Neurol Sci. 1984. 65: 323-331.   DOI   ScienceOn
22 Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000. 275: 16638-16642.   DOI   ScienceOn
23 Ferre P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes. 2004. 53: S43-S50.   DOI   ScienceOn
24 Janssen I, Heymsfield SB, Baumgartner RN, Ross R. Estimation of skeletal muscle mass by bioelectrical impedance analysis. J Appl Physiol. 2000. 89: 465-471.   DOI
25 Jay MA, Ren J. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus. Curr Diabetes Rev. 2007. 3: 33-39.   DOI   ScienceOn
26 Jeong S, Choi WC, Yoon M. Effects of fenofibrate on adipogenesis in female C57BK/6J mice. J Exp Biomed Sci. 2005. 11: 1-8.
27 Jeong S, Choi HK, Yoon M. Morphological changes in adipose and liver tissues by 17-estradiol in female ovariectomized C57BL/6 mice. J Exp Biomed Sci. 2007. 13: 99-104.
28 Jeong S, Kim M, Han M, Lee H, Ahn J, Kim M, Song YH, Shin C, Nam KH, Kim TW, Oh GT, Yoon M. Fenofibrate prevents obesity and hypertriglyceridemia in low-density lipoprotein receptor-null mice. Metabolism. 2004a. 53: 607-613.   DOI   ScienceOn
29 Jeong S, Han M, Lee H, Kim M, Kim J, Nicol CJ, Kim BH, Choi JH, Nam KH, Oh GT, Yoon M. Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice. Metabolism. 2004b. 53: 1284-1289.   DOI   ScienceOn
30 Jeong S, Yoon M. Inhibition of the actions of peroxisome proliferator-activated receptor alpha on obesity by estrogen. Obesity (Silver Spring). 2007. 15: 1430-1440.   DOI   ScienceOn
31 Komi PV, Karlsson J. Skeletal muscle fibre types, enzyme activities and physical performance in young males and females. Acta Physiol Scand. 1978. 103: 210-218.   DOI   ScienceOn
32 Arany Z. PGC-1 coactivators and skeletal muscle adaptations in health and disease. Curr Opin Genet Dev. 2008. 18: 426-434.   DOI   ScienceOn
33 Barger PM, Kelly DP. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med. 2000. 10: 238-245.   DOI   ScienceOn
34 Barter PJ, Rye KA. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol. 2008. 28: 39-46.   DOI   ScienceOn
35 Berger JP, Akiyama TE, Meinke PT. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci. 2005. 26: 244-251.   DOI   ScienceOn
36 Brandt JM, Djouadi F, Kelly DP. Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha. J Biol Chem. 1998. 273: 23786-23792.   DOI   ScienceOn
37 Chai JK, Blaha V, Meguid MM, Laviano A, Yang ZJ, Varma M. Use of orchiectomy and testosterone replacement to explore meal number-to-meal size relationship in male rats. Am J Physiol. 1999. 276: R1366-R1373.
38 Chaput E, Saladin R, Silvestre M, Edgar AD. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun. 2000. 271: 445-450.   DOI   ScienceOn
39 Chou CJ, Haluzik M, Gregory C, Dietz KR, Vinson C, Gavrilova O, Reitman ML. WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. J Biol Chem. 2002. 277: 24484-24489.   DOI   ScienceOn
40 Zhang F, Lavan B, Gregoire FM. Peroxisome proliferator-activated receptors as attractive antiobesity targets. Drug News Perspect. 2004. 17: 661-669.   DOI   ScienceOn